Adjuvant chemotherapy for endometrial cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Trials Research

Background:

• Endometrial cancer treatment often involves surgery and radiation therapy.
• The role of adjuvant chemotherapy remains a subject of investigation, particularly for early-stage and advanced-stage disease with residual tumors.
• Identifying patients most likely to benefit from adjuvant chemotherapy is essential for personalized treatment strategies.

Purpose of the Study:

• To review the efficacy of adjuvant chemotherapy in endometrial cancer.
• To pinpoint patient subgroups who experience significant survival advantages from adjuvant chemotherapy.

Main Methods:

• A comprehensive bibliographic search was performed for randomized trials on adjuvant chemotherapy in endometrial cancer.
• Databases searched included MEDLINE/PubMed, cited references, conference proceedings, and clinical trial registries.
• Data from identified trials were systematically extracted and analyzed.

Main Results:

• Eight randomized trials were identified, with varying patient and treatment characteristics.
• Only two trials demonstrated a significant survival benefit with adjuvant chemotherapy, either alone or post-radiation, compared to radiation alone.
• High-risk features associated with survival benefit included limited lymph node evaluation, nodal metastasis, high-grade/aggressive histology, specific tumor stages (IC, II, IIIA with deep invasion, IIIC-IV).

Conclusions:

• Evidence for adjuvant chemotherapy's survival benefit in endometrial cancer is inconsistent when compared to radiation therapy alone or combined with radiation.
• Adjuvant chemotherapy offers a survival advantage primarily to specific patient groups with identifiable high-risk disease features.
• Clinical decision-making requires careful assessment of individual patient and disease risk factors to guide the use of adjuvant chemotherapy.